Cystic Fibrosis Foundation issued the following clinical trial alerts in February.
February 5, 2021
Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis
Status: Completed with Results
Description: This study evaluated the effectiveness of the inhaled drug vancomycin hydrochloride inhalation powder (AeroVanc) in adults and children 6 years and older with CF and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).
Age: 6 Years to 21 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 30 to 90%
Number of Visits: 13
Length of Participation: 12 months
ClincalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT03181932
February 8, 2021
Status: Enrolling
Description: This study will evaluate children 6 to 18 years old with CF to determine the acceptability and feasibility of a larger trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation treatment.
Age: 6 Years to 18 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 50% or greater
Number of Visits: 3
Length of Participation: 18 months
ClincalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04608019